The Avicenna Alliance is the 1 stop shop for all things in silico and health policy at EU level. Industries and research organisations who are impacted by EU policy in these areas should consider membership of the association. 

Avicenna Alliance Industry Members




Alexion is a global biopharmaceutical company with more than 25 years of experience focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Our mission is to transform the lives of people affected by rare diseases and devastating conditions by continuously innovating and creating meaningful value in all that we do. We continue to deepen our understanding of rare disease, innovating and evolving into new areas where there is great unmet need and opportunity to help patients and families fully live their best lives.

Find out more about Alexion...


Ansys' sole focus is engineering simulation. For more than 50 years, it has consistently advanced this technology to meet evolving customer needs.

Ansys develops, markets and supports engineering simulation software used to predict how product designs will behave in real-world environments. Ansys continually advances simulation solutions by

  • Developing or acquiring the very best technologies
  • Integrating them into a unified simulation platform capable of complex, multiphysics solutions

Providing system services, including high-performance computing (HPC) and Cloud solutions, to manage simulation processes and data.

Find out more about Ansys...

Boston Scientific

Boston Scientific is a leading innovator of less invasive medical solutions that transform lives around the world who is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.

Boston Scientific is fulfilling its brand promise by focusing on solutions that matter most, pursuing excellence and collaborating with healthcare professionals.

Find out more about Boston Scientific...

Computational Life

Computational Life: Computational Life is a company incorporated in Delaware, United States of America founded in 2018. The Mission of Computational Life is to help physicians better manage the multisystemic pathologies with cardiovascular origins, focussing as the first step on patients in shock conditions. Computational Life provides the most advanced predictive software of human-physiology based on physical laws, enabling physicians to manage complex shock conditions by simulating the effects of several different medical treatments. Computational Life’s platform, unlike artificial intelligence software, relies on mathematical models based on deterministic and phenomenological laws. This implies a level of medical accuracy and breadth of patient characterization that has never been achieved so far.

Find out more about Computational Life...

Dassault Systèmes

Dassault Systèmes is a global leader in sustainability. Our purpose is to provide business and people with 3DEXPERIENCE universes where they can imagine sustainable innovations capable of harmonizing product, nature, and life. 

The Dassault Systèmes 3DEXPERIENCE Platform is the first end-to-end scientific and business platform, connecting the dots between people, ideas and data; combining modeling, simulation, data science, artificial intelligence and collaboration in the virtual world to achieve sustainable innovation for life sciences companies catalyzing the next generation of patient-inclusive therapeutics.

Find out more about Dassault Systèmes...

Edwards Lifesciences


Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information follow us on Facebook, Instagram, LinkedIn, Twitter and YouTube.

More information about Edwards Lifesciences…


ELEM harnesses Virtual Humans and supercomputers to transform patient data (scans, biomedical information, etc.) into unparalleled medical insights. Our medical software solutions model diseases and patient anatomy to predict treatment outcomes and improve human health. 

Enabling better treatments, devices or drugs, faster, with improved outcomes for patients and reducing risks, biomedical industries can now conduct, seamlessly, thousands of in-silico experiments and assess multiple patient responses before human trials. 

ELEM is a spin-off from the Barcelona Supercomputing Center and mentorship from EIT Health (Validator), Oracle (OSCA) and SETSquared in Bristol.

Find out more about ELEM...

InsilicoTrials Technologies

InSilicoTrials is the first cloud-based platform that provides healthcare companies and researchers with easy-to-use tools to perform computational modelling and simulation in pharmaceutical and medical devices development.

InsilicoTrials Technologies has been set up by experts in the fields of IT, Clinical Research and Business Information Systems with the aim of offering its customers innovative solutions and advice specializing in the Management of Clinical Trials Information Systems applied to Clinical Research. The experience provided by the company consultants is the result of decades of collaboration with Head Physicians and Companies/Institutions of the Pharmaceutical, Medical and Clinical Research sectors.

Find out more about InsilicoTrials Technologies...

Johnson & Johnson

As a major player in three market segments and with a focus on the full continuum of care – prevention, diagnosis and treatment – Johnson & Johnson competes in fully one-third of the global health care marketplace. Its breadth helps drive consistent performance and enables the company to pursue growth opportunities – including in some of the fastest growing segments of health care – wherever they arise. It allows Johnson & Johnson to respond to purchasing trends with governments and large customers. Perhaps more important, it allows the company to think about patient care holistically, drawing on insights from multiple perspectives in a disease category. In the end, being broadly based allows it to stay true to its Credo in the face of an ever-evolving health care environment.

Find out more about Johnson & Johnson...


Spine deformation concerns millions of patients around the world leading to a significant reduction in their Quality of Life (QoL). Adult spine deformity carries the worst healthcare burden of all chronic conditions. Fusion of the spine might be the treatment but had several limitations and iatrogenic consequences. It had to be well balanced, include the right segments, stop at the appropriate level.  Today, about 40% of these surgeries fail and require revision.  The solution is SPINEsim, a SaMD aimed at helping the surgeon to plan for the optimal surgical strategy and minimize post-op complications and the need for revisions.

Find out more about MDsim...

Mediolanum Cardio Research

Mediolanum Cardio Research (MCR) Srl is an independent Contract Research Organisation (CRO) established in Milano (Italy) since 2002 MCR have gained extensive experience in regulatory authorizations and reporting, project management, monitoring, data management and statistics for sponsored and no-profit clinical trials both pharmacological and Medical Devices.

MCR has also internally developed an electronic CRF (called IDAS), compliant with FDA 21 CFR part 11 and GDPR. In addition, MCR has an internal Core-lab specialised in QCA readings.

MCR is proud to be partner of the Horizon 2020 InSilc project (In-silico trials for drug-eluting BVS design, development and evaluation. Project 777119). One of MCR tasks is to identify and elaborate on the regulatory aspects which have to be fulfilled in order to have in silico trials accepted as part of the clinical assessment of new coronary stents. The adoption of modelling and simulations entails ethical issues and methodological constraints: being member of the Avicenna Alliance could provide an exceptional opportunity to gain and to provide contribution to the development of guidelines for a proper adoption of in-silico clinical trials.

Find out more about Mediolanum Cardio Research...


Medtronic is a global healthcare solutions company committed to improving the lives of people through its medical technologies, services, and solutions.

During the six decades of Medtronic’s existence, its Mission has remained the same: to alleviate pain, restore health, and extend life for people around the world. Medtronic has worked hard to be at the forefront of medical device innovation, challenging itself to develop high-quality therapies that positively impact people’s lives.

Medtronic has accomplished a lot — today more than 62 million people benefit from the company’s technologies each year, equating to two people every second. But, Medtronic also knows that it participates in global healthcare systems that are facing intense clinical and economic challenges. If not corrected, these issues may serve to undermine global growth and development and leave millions around the world untreated — for even the simplest diseases. Medtronic believes that what got it to the current state of healthcare is not necessarily what will propel it forward. The future of healthcare requires new approaches and new forms of innovation.

Find out more about Medtronic...


Mimesis is an innovative start-up, founded in 2020 as a spinoff of the University of Catania, which offers to the biomedical industry and pharmaceutical companies the first generation of in Silico solutions.

These are computational models that can replicate the behaviour of the human immune system, and can simulate its responses both in the presence of viruses, bacteria, tumours and auto-immune diseases, and in the presence of pharmacological therapies: this way, the time and costs of research and drug development are considerably reduced.

The Universal Immune System Simulator (UISS) is the main product produced by Mimesis: thanks to the use of virtual patients, the framework simulates the effects of a given therapy on the immune system, thus reducing the risk of possible side effects and predicting its effectiveness even before its implementation. 

As part of the in Silico World project (HORIZON 2020), Mimesis is committed to reducing regulatory barriers in the adoption of in Silico models. Furthermore, the company cares about ethics: the solutions adopted do not require the use of any humans, leading to a reduction in the number of patients participating in in vivo clinical trials.

Mimesis is the result of more than twenty years of research by its partners. The founding partners, Prof. Francesco Pappalardo and Dr. Giulia Russo, together with the other members, tirelessly carry on the research work, making Mimesis one of the most important start-up in the health sector.

Find out more about Mimesis...


In silico medicine that works

A pioneer in in silico, NOVADISCOVERY offers a transformative approach to drug R&D based on a reverse engineering methodology combining mathematical models of diseases, drugs and virtual patients which enables the assessment of downstream clinical benefit for patients long before trials on humans.

From a technology standpoint, NOVADISCOVERY has developed a full white box ecosystem, called WISEÆ ("Whitebox In Silico Engine"), to streamline its workflows.

We help our partners de-risk their drug programs by analyzing the impact of critical decisions in terms of clinical benefit, optimize the design of in vitro/in vivo assays and reduce time & costs through a cheaper & faster exploration of key assumptions.

Based in Lyon, France, NOVADISCOVERY brings together a multidisciplinary team of experts dedicated to shifting away from the traditional R&D paradigm, characterized by serendipity and costly trial and error, towards a rational patient outcomes-centric model driven by mathematics and computational sciences.

Find out more about NOVADISCOVERY...


Numalogics is a Montréal-based privately held company priding itself on its world-class biomechanical simulation expertise. Founded by renowned orthopaedic and spine surgeons in 2010, the Numalogics team has developed a numerical representation of a human named “Numa”. Our cross-functional team combines the skills of clinicians, biomechanical experts, mechanical engineers, and software developers. The Numalogics virtual lab provides insight into the biomechanics of human-device interaction and the virtual human ‘Numa’ is leveraged to enhance the safety and performance of our clients’ products. 

Find out more about Numalogics...


NumeriCor is a leading cardiac electrophysiology and mechanics modelling company providing end-to-end simulation control. 

Our software is considered most robust, flexible and efficient in the cardiac simulation community as many leading labs rely on both our proprietary and community simulators, CARPentry-Pro and openCARP.

NumeriCor's team around Prof. Gernot Plank comes from leading international labs and have a long-standing track record.

We provide our clients with unique tools for device simulations that allow rapid design iterations, efficient device integration, comprehensive functionalization and data-driven personalization, anatomically and biophysically detailed modelling and Live Preview.

We help our clients to advance their understanding of mechanisms governing device-tissue interaction, leading to better approaches for pacing/defibrillation and ablation therapies.

NumeriCor: from Real-Time to Full Physics. 

Find out more about NumeriCor...


Quibim, a company with its headquarters in Valencia, Spain, is a global leader in whole-body medical imaging analysis. Quibim products are used worldwide by leading research teams. Partners use Quibim Precision®, a whole-body imaging ecosystem, for a wide range of applications from detecting a disease to tracking the efficacy of novel treatments.

Quibim follows an AI-first approach to help detect pathologies across every body part and imaging modality, using quantitative imaging biomarkers. We understand every body part. We speak human.

Find out more about Quibim...

RBF Morph

RBF Morph is a pioneer and leader in mesh morphing, a key technology used in engineering simulation that combines a very accurate control of the geometrical parameters with an extremely fast mesh deformation, fully integrated in the solving process. Our mission is the development and broad application of simulation technology to synthesize and optimize designs, processes and decisions for our customers in any industry that needs to achieve optimal efficiency. RBF Morph jointly offers with Ansys two products, RBF Morph Structures and RBF Morph Fluids, that are fully integrated with Ansys Fluids, Ansys Structures.

The RBF Morph Standalone, fully scriptable with Python, can be used whenever mesh nodes data are reachable and modifiable in some manner, no matter which numerical solver is being leveraged. Our tools enable the accurate generation of statistical shape models to represent and perform numerical simulation on a population of patients and allow the modification of shape parameters for the optimisation of medical devices. We are currently active on projects related to the development of Digital Twins for the ascending aortic aneurysm analysis and treatment (MeDiTATe), the drug delivery in the airways (DiTAiD) and the Modified Blalock Taussig shunting procedure (Copernicus). RBF Morph is based in Monte Compatri, Rome, Italy.

Find out more about RBF Morph...


Personalizing patient care with simulation.

Simq is a certified software developer and simulation service provider in the field of medicine and medical technology.

As a pioneer of in silico medicine, Simq drives the adaptation of innovative and new technologies and provides a platform that enables medical device manufacturers to easily access to in silico medicine and computer simulation and modeling.

Through its extensive research activities, Simq is constantly working on new applications of simulation in medicine and developing them into new products in collaboration with well-known manufacturers.

Find out more about Simq GmbH...



SmartCatch is a deeptech start-up with disruptive technological know-how. Located at the heart of the Toulouse Oncopole, the start-up intends to provide oncology research and treatment centres with a series of cutting-edge microtechnology-based devices that can be used in clinical routine to isolate blood-based biomarkers for longitudinal monitoring of cancerous pathology and customization of the therapeutic strategy.


SmartCatch's core innovation relies on 3D microdevices integrated to customized fluid management platforms for the mild capture of circulating tumor cells (CTC) from whole blood exploiting their physical traits while preserving their native state and improving their representativeness in clinical routine. The company's conviction is to access the clinical market offering dedicated products enabling the implementation of precision medicine at affordable costs with a higher degree of uniformity and standardization, contributing to a principle of equity in healthcare.


Find out more about SmartCatch…


Twinsight offers an online biomechanical modeling and simulation ecosystem providing access to high fidelity digital twins. Our models are based on a corpus of validated functional and structural anatomy.

The Twinsight platform is made available for healthcare professionals as well as medical device industry (implants, orthotics, insoles) in order to:

  • promote better surgical outcomes through surgical planning optimization on an accurate digital twin of the patients created automatically from medical images and/or surfacic 3D scan,
  • promote better design of medical devices through in silico studies on virtual cohorts of simulated patients.

Find out more about Twinsight...


Virtonomy is shortening time-to-market of medical products by conducting data driven studies on virtual patients. Our solution is based on an ever-expanding database to reflect anatomical variability, demographic diversity and pathological conditions.

We support medical device manufacturers in the various phases of the product life cycle, from concept phase, over pre-clinical evaluation to post-market surveillance: better understand the target anatomy, find the optimal fit of the device to treat the maximum number of patients, identify the right in-vivo model, and improve clinical trials by proper sub-population selection.

Virtonomy is headquartered in Munich, Germany, and combines an interdisciplinary team of experts in medical engineering, image and data processing, visualization and clinical practice.

Find out more about Virtonomy...

Voisin Consulting Life Sciences (VCLS)

Voisin Consulting Life Sciences is a global product development consultancy, which guides Biotechnology, Pharmaceutical and Medtech manufacturers throughout product development and commercialization. From discovery to patients, VCLS assists innovators to design product development strategies that optimize clinical development in order to drive commercial success, through an understanding of both regulators and payers.

VCLS’s team of health product specialists seamlessly supplement innovative life sciences companies’ resources with strategic advice and cross-functional operational capabilities. The firm offers integrated solutions to development planning, manufacturing, quality and controls, nonclinical and clinical testing, safety monitoring, and interactions with regulators and payers. With offices in Cambridge, Somerville and San Francisco (MA, CA & NJ, USA), London (UK), Paris and Rennes (France), Lausanne (Switzerland) and Bangalore (India), VCLS serves a broad range of developers and investors.

Find out more about VCLS...

Zimmer Biomet

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.  

More information about Zimmer Biomet...

Representation of VPH Institute



VPH Institute

The Virtual Physiological Human Institute for Integrative Biomedical Research, in short VPH Institute, is an international non-profit organisation incorporated in Belgium, whose mission is to ensure that the Virtual Physiological Human is fully realised, universally adopted, and effectively used both in research and clinic.

Since its establishment the VPH Institute has been collaborating with the community and the European Commission on different initiatives. In particular it contributed to the support action Discipulus, and it is now partners of Avicenna.

Find out more about the VPH Institute...

Avicenna Alliance news

Welcome to our new member MDsim!

We are delighted to welcome our new member MDsim!

MDsim is a health-tech start-up, based in Luxembourg, active in the In-Silico Medicine. 

find out more ›

Mapping the use of computational modelling and simulation in clinics: A survey

Computational modelling and simulation (CM&S) can be used in medicine to mimic biological processes with the goal of...

find out more ›

Nathalie Virag is the new Avicenna International Affairs Working Group Leader!

Nathalie Virag, Ph.D is a Distinguished Scientist at Medtronic Corporate Technology & Innovation. She has more than 25...

find out more ›

Second release of Avicenna Glossary now available!

This Glossary is a second release with an extended list of definitions; more concepts will be defined and existing definitions may be adjusted in...

find out more ›

We are delighted to welcome France Biotech as a new Avicenna Partner

Founded in 1997, France Biotech is an independent association, uniting the country’s leading innovative health companies and their...

find out more ›

The potential of in silico approaches to streamline drug development

This position paper highlights the potential of in silico medicine, using computational modelling and simulation to aid drug...

find out more ›


We will give the entire healthcare community an exhaustive update on recent progress and achievements related to the adoption and deployment of in silico method...

find out more ›

Avicenna Alliance Observer at IMDRF meeting in Brussels

The Avicenna Alliance had received the honor to be invited as an Observer to the International Medical Device Regulators Forum (IMDRF) meeting...

find out more ›

Avicenna Alliance meets with MEPs in Strasbourg

During the European Parliament’s plenary session that took place in the second week of March, Avicenna had the unique opportunity to visit the European...

find out more ›

Welcome RBF Morph!

Welcome to our new member RBF Morph! Based in Monte Compatri, Rome, RBF is a pioneer and leader in mesh morphing, a key technology used in engineering simulation.

find out more ›

Mimesis is a new Avicenna member!

We are truly delighted to welcome Mimesis as a new Avicenna member!

Mimesis is an innovative start-up, founded in 2020 as a spinoff of the University of Catania,...

find out more ›

Shiny Martis is the new Pharmaceutical Strategy TF Co-Chair

We are delighted to welcome Shiny Martis as the new Pharmaceutical Strategy TF Co-Chair.

Shiny is Academic Partnership and Customer...

find out more ›

Numalogics is a new Avicenna member

We are honored to welcome Numalogics as a new Avicenna’s member!
Numalogics is a Montréal-based privately held company priding itself on its world-class...

find out more ›

Congratulations to our new Working Group Leaders!

We are delighted to welcome Cécile Rousseau and Martha De Cunha who have been elected as new Working Group Leaders of the Avicenna's 

In Silico... find out more ›

In Silico Application (ISA) Working Group

Digital evidence can and must be used for regulatory approval in all parts of the world. The Research & Technology Working Group has made huge progress,...

find out more ›

Working Group Leaders elections

Our warmest congratulations to Liesbet Geris and Mark Palmer for their reappointment as Working Group Leaders of the Avicenna's Research & Technology Working Group and...

find out more ›

We are delighted to welcome NumeriCor as a new Avicenna member!

NumeriCor is a leading cardiac electrophysiology and mechanics modelling company providing end-to-end simulation control. 

find out more ›

Avicenna Alliance Glossary of Terms for Computer Modeling and Simulation

There are occasional confusions and diverging opinions possibly leading to misunderstanding in the use of some In Silico...

find out more ›


A range of authors across academia and industry, representing both the Avicenna Alliance and the Virtual Physiological Human Institute,...

find out more ›

Toward a regulatory pathway for Using in Silico Trials in CE Marking of Medical Devices


A team of researchers of the In Silico World project, including several key Avicenna Alliance members, led...

find out more ›

Avicenna Alliance response to the ICHE11A Consultation

The Avicenna Alliance strongly supports and welcomes the ICH’s proposed goal of harmonizing methods and strategies for improved paediatric drug...

find out more ›

Avicenna Alliance Feedback to the European Health Data Space Call for Feedback

The Avicenna Alliance welcomes the proposal for the EHDS. The Alliance is a multistakeholder group with the mission of...

find out more ›

We are honored to welcome Zimmer Biomet as a new Avicenna’s member!

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve...

find out more ›

Avicenna Alliance Response to 2023 Stakeholders' Targeted Consultation on EU4Health

The Avicenna Alliance stressed the need for further support and guidance for digital evidence from in silico...

find out more ›

New Avicenna APAC Task Force

A new Task Force joined the International Affairs Working Group!

find out more ›

Cécile De Coster is the new Avicenna Pharmaceutical Strategy Task Force Co-chair

We are proud to welcome Cécile De Coster as the new Avicenna Pharmaceutical Strategy Task Force co-chair!

find out more ›

Avicenna Alliance goes on growing by welcoming Edwards Lifesciences as a new member!

Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and...

find out more ›

Avicenna Alliance is honoured to welcome Alfasigma as a new member!

Privately owned, Alfasigma is one of the leading Italian pharmaceutical companies, present in over 90 countries, through...

find out more ›

EU-funded project successfully develops AI software that grows and treats cancerous tumors 

The Horizon Europe 2020 project EVO-NANO (Evolvable platform for programmable nanoparticle-based cancer...

find out more ›

In silico used to validate Omicron variant detection method! 

The Joint Research Centre (JRC) has developed a new method to detect the Omicron variant of COVID-19, which differs in its nucleic acid...

find out more ›

The priorities of the upcoming French Presidency of the Council of the European Union - what’s new for Avicenna? 

The French Presidency of the Council of the European Union is due to start on 1...

find out more ›

New Avicenna UK Insilico Regulatory Innovation Task Force

The Avicenna International Affairs Working Group adds a new task force to its structure.

find out more ›

In Silico in Innovation – again!

The European Innovation Council (EIC) has released its second wave of “start-up champions” to receive funding for innovations through the EIC Accelerator. The EIC...

find out more ›

Avicenna Alliance meets with MEPs to discuss in silico medicine

On 7 October, Dr. Liesbet Geris (Research Professor in Biomechanics and Computational Tissue Engineering at the Universities of Liège &...

find out more ›

The Joint Research Centre advocates for a “paradigm change” to in silico research methods!

For the second week in a row, the Joint Research Centre (JRC) – part of the European Commission’s EU Science...

find out more ›

The European Commission Joint Research Centre publishes a public knowledge base of non-animal models used in immuno-oncology

The Joint Research Centre (JRC), which is part of the European...

find out more ›

The State of the (European) Union

On 15 September, Commission President Ursula von der Leyen delivered her second State of the Union speech at the European Parliament in Strasbourg. She took stock of...

find out more ›

The BECA Beat 

The European Parliament’s Special Committee on Beating Cancer (BECA) met for the first time in September of 2020. BECA was established to create actionable recommendations for Member...

find out more ›

Avicenna Alliance prepares for the next EU policy session 

As September begins, politicians have returned to their EU posts and are preparing for what will be a busy few months for health policy. The...

find out more ›

Joint Research Centre of the Commission launches report on national strategies for Artificial Intelligence!

The Joint Research Centre of the European Commission (JRC) recently published a new report...

find out more ›

Conference of the Slovenian Council Presidency addresses digital twin technologies and digitalisation in healthcare!

On 15 and 16 July, the Slovenian Presidency of the Council of the European Union ...

find out more ›

WHO issues first global report on use of AI in healthcare

Artificial Intelligence (AI) applications in health innovation are rapidly increasing, reflecting the potential of these technologies to...

find out more ›

Slovenian Presidency of the Council of the EU launches its six-month programme!

On 1 July, for the second time since joining the EU in 2004, Slovenia has taken over the Presidency of the Council of...

find out more ›

Members of the European Parliament call EU Health Commissioner to place in silico medicine on her policy agenda from 2021 onwards!

On 22 June, a group of five Members of the European Parliament...

find out more ›

Our new position paper on in silico evidence in the regulatory approval of medical devices is out!

The Avicenna Alliance is proud to announce the recent publication of its new position paper...

find out more ›

Happy 5th Anniversary to the Avicenna Alliance!  

5 years ago, based on the very enlightening Avicenna Roadmap Project Report, the Avicenna Alliance was established at the suggestion of European...

find out more ›

EU New Medical Device Regulation now in force! In silico mentioned for the first time

After a one-year postponement following the COVID-19 pandemic, the European Commission’s Medical Devices...

find out more ›

The European Commission adopts Communication on Europe's global approach to cooperation in research and innovation

On 18 May, the European Commission adopted a Communication on its global approach...

find out more ›

Avicenna Alliance provides feedback on the European Commissions’ roadmap for the revision of the EU general pharmaceuticals legislation

On 27 April, the Avicenna Alliance has submitted its feedback...

find out more ›


find out more ›

Show all activites

Sign up for our monthly newsletter!

Sign up